WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H414371
CAS#: 93-47-0
Description: Verazide is a Tuberculostatic
Hodoodo Cat#: H414371
Name: Verazide
CAS#: 93-47-0
Chemical Formula: C15H15N3O3
Exact Mass: 285.11
Molecular Weight: 285.300
Elemental Analysis: C, 63.15; H, 5.30; N, 14.73; O, 16.82
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Verazide; Nicotazide; NSC180261; NSC-180261; NSC 180261
IUPAC/Chemical Name: (E)-N'-(3,4-dimethoxybenzylidene)isonicotinohydrazide
InChi Key: HPXIKMBHOXLFOR-LICLKQGHSA-N
InChi Code: InChI=1S/C15H15N3O3/c1-20-13-4-3-11(9-14(13)21-2)10-17-18-15(19)12-5-7-16-8-6-12/h3-10H,1-2H3,(H,18,19)/b17-10+
SMILES Code: COc1c(OC)cc(/C=N/NC(c2ccncc2)=O)cc1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 285.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: RUBBO SD, CYMERMAN-CRAIG J. Anti-tuberculous activity of verazide (1-isonicotinoyl-2-veratrylidene hydrazine). Nature. 1955 Nov 5;176(4488):887. doi: 10.1038/176887a0. PMID: 13272716.
2: RUBBO SD, ROUCH LC, EGAN JB, WADDINGTON AL, TELLESSON WG. Chemotherapy of tuberculosis. III. Verazide in the treatment of pulmonary tuberculosis. Am Rev Tuberc. 1958 Aug;78(2):251-8. doi: 10.1164/artpd.1958.78.2.251. PMID: 13559656.
3: RUBBO SD, EDGAR J, VAUGHAN G. Chemotherapy of tuberculosis. I. Antituberculous activity of verazide and related hydrazones. Am Rev Tuberc. 1957 Sep;76(3):331-45. doi: 10.1164/artpd.1957.76.3.331. PMID: 13458717.
4: BARBOLINI G, LOSCHI GC. [Clinico-biological observations on the use of verazide in the therapy of pulmonary tuberculosis]. Clin Ter. 1961 Mar;20:253-73. Italian. PMID: 13686822.
5: RUBBO SD, VAUGHAN G. Chemotherapy of tuberculosis. II. Some observations on the pharmacology of verazide. Am Rev Tuberc. 1957 Sep;76(3):346-59. doi: 10.1164/artpd.1957.76.3.346. PMID: 13458718.